A camera walks into a laboratory
The pitch, in one paragraphRon Zohar co-founded a company whose central bet is that the phone in your pocket - the one that autocorrects "duck" wrong - is a clinical-grade medical instrument if you just hand it the right piece of paper.
The right piece of paper, in Healthy.io's case, is a small color chart printed with laboratory precision. Point the phone at a used urine dipstick alongside the chart. The camera captures both. Software normalizes the lighting against the reference colors, reads the strip, and returns a result that hospital labs recognize. It is not a party trick. It is FDA-cleared. And the company Ron Zohar co-founded in Tel Aviv in 2013 has spent a decade convincing regulators, health plans, and skeptical clinicians that a smartphone, correctly calibrated, is a device. Healthy.io's own leadership page describes him as an executive at the company; earlier filings with the U.S. Food and Drug Administration list him as Chief Product Officer, the authorized signer on the 510(k) submissions that turned the pitch into an approval. He wears the title of a co-founder now, and the company's product story has his fingerprints on it.
The trick works because color is data if you control the reference. Zohar's team - alongside Healthy.io's founder Yonatan Adiri and chief scientist Ido Omer - built the calibration workflow, the computer-vision pipeline, and the regulatory dossiers that stitched them together. The urinalysis product came first. Then wound care, where a similar problem (measuring something visible using a phone) gets solved with the same instinct: give the camera reference points, let algorithms do the interpretation, and route the result to a clinician. Patent filings on the wound-imaging work list Zohar as an inventor. In a company that publishes surprisingly little press about individual employees, that is how you know who did the work.
"The camera in your hand is a scientific instrument. Someone just has to hand it the right calibration target."
Before Healthy.io, Zohar had two lives. The first was in the Israeli Air Force, where he served as an officer. The second was in consumer software. He co-founded Groovideo, a real-time video creation startup, well before real-time video was cool. He then joined Fiverr as a mobile product manager, shipping the marketplace's mobile apps in the years leading up to its 2019 IPO. The through-line between video tools, marketplace apps, and medical imaging is more coherent than it sounds. All three are variations on the same problem: convincing a smartphone camera to do something it was not exactly designed for, and packaging the result so a non-technical human can trust it. He then went to Harvard Business School's Program for Leadership Development, the executive program favored by operators who would rather build things than run for CEO.
Healthy.io's mission statement - "healthcare at the speed of life" - is standard-issue digital-health boilerplate. What is not standard is the number of regulatory clearances it has stacked up while sounding boring in press releases. The company has raised roughly $140 million in total, most recently a Series D round in 2023. Its investors include health-plan partners; its go-to-market includes contracts with U.S. insurers who mail test kits to members and use the results to catch chronic kidney disease earlier. It is the sort of company that gets described as "a phone-based diagnostics company," which undersells the actual work: getting a regulator to agree that an ordinary Android and iPhone camera can be a covered medical device, at population scale, in kitchens.
Physics + philosophy + Air Force + Fiverr = a resume that reads like a category error and a company that reads like a thesis.
In January 2024, Healthy.io announced that Geoff Martin, a longtime healthcare operator, would take the CEO role. Founder Yonatan Adiri moved to President. The reshuffle is normal for a Series D-stage medical device company that is trying to scale into U.S. commercial contracts; scaled operations tend to want experienced operators. Zohar remains a co-founder and a technology leader inside the company. He rarely tweets. His Twitter handle in public databases points to the company's account, not a personal soapbox. He posts on LinkedIn when the company gets a clearance. It is a quiet public presence for someone whose name is on the patents.
One useful way to read Zohar's career is to notice what he did not do. He did not become a founder-CEO who chased conference stages. He did not raise a mega-round on a pre-product deck. He did not pivot Healthy.io to whatever was in the AI news cycle that week. Instead the company kept building the same technical stack - color reference charts, computer vision, regulatory submissions, health-plan integrations - and gradually broadened its use cases from urinalysis to at-home UTI testing to wound imaging to a1c testing at home. The engineering discipline that comes out of building marketplaces (measure everything, ship, iterate) is compatible with the engineering discipline that comes out of physics (measure the reference, control the noise, report the confidence). Zohar sits at the intersection.
The Tel Aviv office at 2 Shlomo Ibn Gabirol Street is a five-minute walk from the sea. Healthy.io employs around 110 people there and in New York. Its product lines carry a family name - "Minuteful" - and its clinical partners tend to be the sort of large payer networks whose logos you would recognize on the back of an insurance card. Zohar's email at the company still bears the founder's short address, ron@healthy.io. It is the sort of small tell that gives away seniority in a company that has grown past the age where anyone thinks about how usernames are assigned.
There are two kinds of digital-health companies. The first sells software to hospitals. The second sells FDA-cleared devices to patients through payers. The first is easier to build. The second is what Ron Zohar chose. It is slower, more regulated, and requires an unfashionable amount of paperwork. It is also the reason his company's products can be shipped to a Medicaid member in rural America and read as if they came from a lab in Boston.